Caffeine and incidence of dyspnea in patients treated with ticagrelor

Am Heart J. 2018 Jun:200:141-143. doi: 10.1016/j.ahj.2018.02.011. Epub 2018 Feb 16.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / metabolism
  • Aged
  • Caffeine* / administration & dosage
  • Caffeine* / adverse effects
  • Caffeine* / pharmacokinetics
  • Drug Monitoring / methods
  • Dyspnea* / diagnosis
  • Dyspnea* / drug therapy
  • Dyspnea* / physiopathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Ischemia* / drug therapy
  • Myocardial Ischemia* / metabolism
  • Myocardial Ischemia* / physiopathology
  • Patient Reported Outcome Measures
  • Purinergic P2Y Receptor Antagonists / administration & dosage
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Purinergic P2Y Receptor Antagonists / pharmacokinetics
  • Ticagrelor* / administration & dosage
  • Ticagrelor* / adverse effects
  • Ticagrelor* / pharmacokinetics

Substances

  • Purinergic P2Y Receptor Antagonists
  • Caffeine
  • Ticagrelor
  • Adenosine

Associated data

  • ClinicalTrials.gov/NCT02311088